The following article features coverage from the IASLC North America Conference on Lung Cancer 2019 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Checkpoint inhibitor immunotherapy is a promising avenue of treatment for non-small cell lung cancer (NSCLC), but researchers have not yet identified biomarkers that can predict patient response to treatment with a high degree of accuracy. Research presented at the International Association for the Study of Lung Cancer (IASLC) 2019 North America Conference on Lung Cancer (NACLC 2019) in Chicago, Illinois, combined clinical factors and radiomic data to devise risk models that can predict survival outcomes for patients with NSCLC who receive immunotherapy.1

Ilke Tunali, PhD, of the Moffitt Cancer Center in Tampa, Florida, led the study, which included 270 patients with NSCLC who were treated with checkpoint blockade immunotherapy. The patients were split into training (180 patients) and test cohorts (90 patients). Overall survival (OS) and progression-free survival (PFS) were the main study endpoints. The researchers used a classification and regression decision-tree statistical method that divided patients into 4 risk groups ranging from “low” to “very high,” based on radiogenomics and clinical factors, and followed the patients’ 3-year disease progression and survival. 

Related Articles

None of the patients whom the models identified as “very-high risk” achieved 3-year overall survival (hazard ratio [HR], 5.35; 95% CI, 2.14-13.36), while those in the “very-low risk” group had a 38.9% 3-year overall survival rate (HR, 1.00). In addition, the researchers found that a statistical tool they used to evaluate radiomics data, called the Gray-Level Co-Occurrence (GLCM) inverse difference, was highly informative and associated with overall survival.

Continue Reading

“This model has important translational implications to identify a highly vulnerable subset of patients not likely to benefit from immunotherapy,” the authors wrote.

Read more of Cancer Therapy Advisor‘s coverage of the IASLC NACLC 2019 meeting by visiting the conference page.


  1. Tunali I, Tan Y, Eschrich S. Clinical-radiomic models predict overall survival among non-small cell lung cancer patients treated with immunotherapy. Presented at: International Association for the Study of Lung Cancer (IASLC) 2019 North America Conference on Lung Cancer (NACLC 2019); October 10-12, 2019: Chicago, Illinois. Abstract OA02.05